Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | |
|---|---|
| Revenue | $0 |
| Cost of revenue | $0 |
| Gross profit | $0 |
| Gross margin | — |
| R&D | $0 |
| Operating income | −$1.2M |
| EBITDA | −$1.2M |
| Net income | −$3.9M |
| Net margin | — |
| EPS (diluted) | -0.88 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds BUGVF.
No tracked institution reports a position in BUGVF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2020-08-26 | 1-for-15reverse |
No one on the platform has traded BUGVF yet.
| $17 |
| — |
| RFCSRefocus Group, Inc. | $0.00 | +0.00% | $25 | — |
| ROIXResponse Oncology, Inc. | $0.00 | +0.00% | $12 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.